GDF8 and GDF11 for Definitive Endoderm Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for efficiently differentiating human embryonic stem cells (hESCs) into definitive endoderm and pancreatic endoderm cells are not sufficiently effective, particularly when using combinations of TGF-beta superfamily proteins and Wnt3a, as they often result in incomplete or inefficient differentiation.
Innovation Solution
The use of specific concentrations of GDF8 and GDF11 proteins, either alone or in combination, to induce pluripotent human cells to differentiate into definitive endoderm cells, followed by further culture to produce pancreatic endoderm cells, with the addition of Wnt3a and small molecule GSK3-beta inhibitors to enhance differentiation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If combinations of TGF-beta superfamily proteins and Wnt3a are used for differentiation, then differentiation is initiated, but differentiation efficiency is insufficient and incomplete
Solution Approach 1:
The patent optimizes the concentration parameters of GDF8 and GDF11 proteins to achieve efficient differentiation. Specifically, GDF8 is used at concentrations of 50-200 ng/ml and GDF11 at 50-200 ng/ml, with specific embodiments using 100 ng/ml for both proteins. This parameter optimization resolves the contradiction by finding the optimal concentration range that maximizes both differentiation efficiency and completeness.
Solution Approach 2:
The patent combines multiple growth factors (GDF8, GDF11, and Wnt3a) to create a composite differentiation system. This combination approach leverages the synergistic effects of different TGF-beta superfamily members and Wnt signaling to achieve complete and efficient definitive endoderm differentiation, resolving the insufficiency of using single factors alone.
2Productivity
If other TGF-beta family members are used, then differentiation can occur, but efficiency and specificity are lower compared to GDF8/GDF11
Solution Approach 1:
The patent identifies that GDF8 and GDF11 have superior local quality for definitive endoderm differentiation compared to other TGF-beta family members. These specific proteins induce higher expression of definitive endoderm markers (SOX17, FOXA2) and produce more homogeneous cell populations with greater than 80% definitive endoderm cells, providing localized optimization for this specific differentiation pathway.
Solution Approach 2:
The patent uses relatively high concentrations of GDF8 and GDF11 (50-200 ng/ml, specifically 100 ng/ml) to ensure complete and specific differentiation. This excessive action approach guarantees that sufficient signaling is provided to achieve near-complete differentiation into definitive endoderm, overcoming the lower efficiency and specificity observed with other TGF-beta family members at comparable concentrations.
Data Source
Figure 1
Figure 2A~2E
Figure 3A~3C
AI summary
Disclosed herein are methods for generating endoderm lineage type cells derived from human pluripotent cells, such as human embryonic stem cells, by using various agents including, but not limited to, GDF8, GDF11 and GSK-3beta inhibitors. Also disclosed herein are endoderm lineage cell populations or compositions, such as populations or compositions comprising definitive endoderm and/or other definitive endoderm-derived cell types.